Physician profile
Mary E Crecelius
NPI 1841272861
$1,759.57
in general payments reported to CMS, 2019-2025
23 companies · $151 in 2025
The $151 reported for 2025 was more than what a typical Women'S Health (Nurse Practitioner) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $320 · 2022: $525 · 2023: $632 · 2024: $131 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $914.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $415.39 | 2021-2024 | Myrisk |
| Abbvie INC. | $364.98 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $124.07 | 2023 | Farxiga |
| Nestle Healthcare Nutrition INC. | $73.40 | 2023 | |
| Lilly USA, LLC | $71.83 | 2024 | Mounjaro |
| Idorsia Pharmaceuticals US INC | $69.62 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $69.45 | 2023 | Austedo Xr |
| Novo Nordisk INC | $65.87 | 2025 | Ozempic |
| Amgen INC. | $64.35 | 2021-2022 | |
| Ascend Therapeutics US, LLC | $62.19 | 2021-2023 | |
| Astellas Pharma US INC | $58.98 | 2023-2025 | Veozah |
| Avion Pharmaceuticals | $51.49 | 2021-2022 | |
| Hologic Sales and Service, LLC | $40.08 | 2023-2024 | Localizer, Third Wave, Thinprep 2000 Processor |
| Exact Sciences Corporation | $37.60 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $30.48 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $25.00 | 2022 | |
| Exeltis, USA INC. | $23.35 | 2025 | Slynd |
| Sumitomo Pharma America, INC. | $22.26 | 2025 | Myfembree |
| Organon LLC | $18.46 | 2022-2023 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $18.23 | 2022 | |
| Therapeuticsmd, INC. | $18.07 | 2022 | |
| Allergan, INC. | $17.58 | 2022 | |
| Virtus Pharmaceuticals LLC | $16.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Crecelius listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.